Table 3 Implementation of preventive chemotherapy in 2014 using ALB/MEB/PZQ against STHs and schistosomiasis among PreSAC and SAC in Rwanda
Age group | Type of worm infection | Population requiring preventive chemotherapy | Number of children targeted | Reported number treated | Programme coverage | National coverage |
|---|---|---|---|---|---|---|
Pre-SAC | Round 1- Albendazole/mebendazole | |||||
STH | 948,314 | 1,295,177 | 1,252,185 | 96.68% | 100% | |
Round 2- Albendazole/mebendazole | ||||||
948,314 | 1,295,177 | 1,241,007 | 95.82% | 100% | ||
School aged children | Schistosomiasis/STH | Round-1 Albendazole/Praziquantel | ||||
2,326,209 | 177,688 | 174,762 | 98.35% | 7.51% | ||
Round-2 Albendazole/mebendazole | ||||||
2,326,209 | 3,177,065 | 3,026,425 | 95.26% | 100% | ||